What Is an Informed Consent Form (ICF) in Clinical Trials?

Introduction

A 2024 analysis of 5,239 US-based ICFs from ClinicalTrials.gov found that the average Flesch-Kincaid Grade Level across those documents was 10.99, corresponding roughly to late 11th grade in the US schooling system and nearly three grade levels above the 8th-grade standard that IRBs and regulatory agencies recommend ^[1]. The documents asking patients to make one of the most consequential decisions of their lives are, by measurable criteria, written for a reading ability that a substantial portion of the adult population does not have.

That gap between what an ICF is supposed to do and what it routinely achieves sits at the center of a persistent question: what does informed consent actually mean in modern clinical research, and what should the document facilitating it look like? Every site coordinator who has watched a participant flip through 30 pages of consent text, nod politely, and sign without asking a single question has confronted this question in practice.

The Informed Consent Form is the document through which a prospective trial participant, before any study-specific procedure takes place, voluntarily agrees to participate in a clinical investigation after receiving all the information required to make that decision freely. The operative word is "informed." The form is the written record of a process, not a substitute for it.

Why This Topic Matters in Clinical Trials

The ICF is not a legal formality that gets handled at enrollment and then filed away. Serious deficiencies in ICF execution can compromise individual study data, trigger IRB suspension of enrollment, or result in regulatory sanctions against a sponsor or investigator, up to and including FDA warning letters and, in cases of deliberate disregard for participant rights, referral for civil or criminal enforcement. In practice, the most common consequences are narrower: protocol deviations requiring documentation, corrective action, and IRB notification. Depending on the nature of the violation and the sponsor's quality management assessment, affected participant data may be excluded or enrollment may be reversed, though these determinations are made case by case and are not automatic outcomes of any specific deviation type.

The ethical and legal obligation to obtain informed consent traces back to the Nuremberg Code of 1947, the first major international document to establish that voluntary consent is an absolute requirement in human research ^[2]. The Code emerged directly from the post-war trials of Nazi physicians who conducted experiments on concentration camp prisoners without consent. The Declaration of Helsinki, adopted by the World Medical Association in 1964 and most recently amended in October 2024 at the 75th WMA General Assembly, extended those principles to medical research more broadly and remains a foundational reference in clinical trial ethics worldwide ^[3]. The 1979 Belmont Report then gave the US regulatory framework its philosophical structure, establishing respect for persons, beneficence, and justice as the three governing principles of ethical human subjects research ^[4].

Every ICF currently in use in a US clinical trial can be traced, through FDA regulations and ICH GCP, back to those documents. The chain of ethical inheritance is not incidental. It is the reason ICF deficiencies receive the regulatory attention they do.

From a purely operational standpoint, an ICF that fails IRB review delays site activation. An ICF that is executed incorrectly constitutes a protocol deviation whose consequences scale with its nature. A consent form that participants do not understand raises questions about whether consent was genuinely informed at all, which is a question that regulatory inspectors and data safety monitoring boards now take seriously.

Current Evidence and Research Landscape

The readability problem is the most consistently documented issue in the ICF literature. A study of 399 ICFs drawn from FDA investigational device exemption applications found that mean reading grade levels ranged from 10th grade to college level when measured across four standard readability tools, all substantially above the recommended 6th-to-8th grade range ^[5]. The 2024 ClinicalTrials.gov analysis of more than five thousand consent forms, covering studies initiated from 2005 to 2024, confirmed an average Flesch-Kincaid Grade Level of 10.99, and found that while there is a modest trend toward improvement in more recent years, the gap between recommended and actual readability has not closed meaningfully ^[1].

The problem is not limited to the United States. A study of ICFs approved by the National Health Research Ethics Committee in Tanzania found comparable complexity, with forms routinely exceeding recommended length and using technical terminology that resists accurate translation into local languages ^[6]. The same Tanzanian study cites background literature reporting that more than half of ICFs reviewed in Iran, Ireland, the UK, Norway, and China were rated difficult to read ^[6].

Readability matters because comprehension drives the legitimacy of consent. When participants do not understand what they are agreeing to, the ethical foundation of the trial is compromised, regardless of how many regulatory boxes the document checks. IRBs are increasingly scrutinizing not just whether required elements are present, but whether the form can be understood by the population who will sign it.

The more operationally significant signal is adoption by large sponsors: according to an industry infographic published by Signant Health, a commercial eConsent vendor, all ten of the top ten pharmaceutical companies by trial volume had implemented eConsent programs, as had 88% of the top 25 ^[15]. This figure is a vendor self-report and has not been independently verified.

The regulatory basis for eConsent rests primarily on the joint FDA/OHRP guidance "Use of Electronic Informed Consent: Questions and Answers," finalized in December 2016, which established that electronic systems and processes may be used to obtain and document informed consent for FDA-regulated clinical investigations ^[8]. The FDA's August 2023 informed consent guidance for IRBs, investigators, and sponsors affirms this position and references the 2016 eConsent guidance directly ^[8a]. During the COVID-19 pandemic, use of eConsent in trials rose approximately 600% over 2019 levels according to GlobalData's Trials Intelligence platform, though that figure is a commercial platform estimate and adoption pulled back significantly after 2022 as site-based recruitment resumed ^[9].

Operational Impact for Sponsors, CROs, and Sites

Where ICF Errors Actually Occur

ICF-related deviations fall into a predictable set of categories: wrong version used at a site after an amendment, consent obtained after a prohibited screening procedure, missing investigator or participant signature or date, and consent administered by a person not authorized under the protocol. These are not rare events. Each represents a failure at a specific process step, not a document flaw, which is precisely why FDA guidance characterizes informed consent as an ongoing process rather than a one-time document transaction ^[8a].

The consequences scale with the nature of the deviation. A missing date on a signed form is a minor deviation that can often be addressed through source documentation and a corrective note. Consent obtained after a protocol-specific laboratory draw that should have required prior consent is a more serious event that typically warrants sponsor and IRB notification ^[8a]. Depending on the protocol's eligibility structure and the sponsor's assessment, enrollment of that participant may be reversed, though outcomes vary by study and circumstance.

From a startup timeline perspective, ICF review and revision is one of the more time-consuming elements of site activation. Sponsors provide a template; sites redline it to satisfy local IRB requirements; the sponsor reviews and approves; the revised form goes back to the IRB before use. In multi-site trials, this cycle runs in parallel across dozens of sites, each with a different IRB, and version control absorbs substantial coordinator and project management capacity.

The Amendment Problem

Every protocol amendment that changes inclusion/exclusion criteria, study procedures, risks, or investigator contact information requires a corresponding ICF amendment. Participants already enrolled must be re-consented on the amended form before the new protocol version takes effect, where they are affected by the changes. Tracking which participants have been consented on which version, which sites have IRB approval for the amended form, and which site coordinators have confirmed re-consent completion is an operational challenge that grows with the number of sites and the cumulative number of amendments.

Language and Literacy

In global trials, ICFs must be translated into local languages by qualified translators and, in many jurisdictions, back-translated to verify accuracy. A participant who signs a translated form they cannot read has not provided informed consent in any meaningful sense. Ethics committees in many countries review translated versions directly before approving their use, adding another approval dependency to the startup timeline.

Regulatory and Documentation Considerations

US Framework: 21 CFR Part 50

FDA regulations governing informed consent in clinical investigations are codified in 21 CFR Part 50. The basic elements required in every ICF are specified at 21 CFR 50.25(a) ^[10]:

Additional elements are required where applicable: disclosure that results could affect insurability, that new findings will be shared with participants, and that information about biospecimen storage or future research use is provided where relevant ^[10]. For applicable clinical trials subject to ClinicalTrials.gov registration requirements, an exact statement notifying participants that trial information will be available on the registry is required under 21 CFR 50.25(c) ^[10].

ICH E6(R3): The GCP Standard

ICH E6(R3) was formally adopted by the EMA in December 2024, with a legal effective date of 23 July 2025 ^[11]. It establishes that informed consent is "an integral feature of the ethical conduct of a trial" and requires that participation be voluntary and based on a consent process that ensures participants are well-informed before agreeing to join ^[12]. The updated guideline explicitly accommodates electronic consent and remote consent processes, reflecting the operational reality of decentralized and hybrid trial designs. Where a minor is a participant, assent should be collected in accordance with local regulatory requirements ^[12].

The FDA-OHRP Joint Guidance on Key Information

In March 2024, the FDA and HHS Office for Human Research Protections jointly issued a draft guidance titled "Key Information and Facilitating Understanding in Informed Consent," updated in February 2025 ^[13]. The guidance responds to a 2018 revision of the Common Rule (45 CFR 46) that introduced a requirement for consent documents to begin with a concise, focused presentation of the information most likely to influence a participant's decision. It recommends formatting approaches, including rounded information boxes, multiple columns, bullet points, and generous white space, to reduce cognitive load and prevent the information overload that lengthy ICFs routinely produce ^[13]. The underlying principle is that completeness of disclosure is not the same as comprehension of disclosure, and regulatory expectations now address both.

IRB Approval and Version Control

No ICF may be used at a site until both the sponsor and the site's IRB or independent ethics committee have approved it. Any revision requires re-approval before use. The person obtaining consent must be authorized to do so under the protocol, and the process must be documented in source records. A copy of the signed form is given to the participant; the original is retained by the investigator and is subject to inspection by the sponsor, IRB, and regulatory agencies ^[10]. The specific documentation requirements; including that the consent form be signed and dated by the subject or legally authorized representative before participation; are codified at 21 CFR 50.27 ^[16].

AI and Automation in ICF Development

What AI Can Reasonably Help With

A 2025 peer-reviewed study published in JMIR Medical Informatics evaluated the Mistral 8x22B large language model's performance in generating the key information sections of ICFs from four clinical trial protocols ^[14]. The LLM-generated sections outperformed human-generated counterparts on readability (mean Flesch-Kincaid grade level of 7.95 versus 8.38), understandability (90.6% versus 67.2%, p=.02), and achieved a perfect actionability score compared to zero for the human-generated versions ^[14]. The scope of the study was limited: four protocols, and specifically the key information section rather than full ICF documents. The results are promising but not yet generalizable to production ICF generation across diverse trial types and therapeutic areas.

The practical use cases for AI assistance are relatively well-defined: drafting an initial ICF from a finalized protocol, simplifying existing consent language to approach the 8th-grade recommended reading level, flagging missing required elements against a regulatory checklist, and generating translated versions as input for qualified human review and back-translation. None of these tasks replaces the human judgment required to verify that a form accurately represents what participants will actually experience.

That last point matters. An AI system generates ICF language based on what is in the protocol. If the protocol's description of a procedure is incomplete, ambiguous, or understates risk, the AI-generated ICF will inherit those problems. The quality of the output is bounded by the quality of the input, which means ICF generation and protocol development are directly interdependent.

What AI Cannot Do

The informed consent process requires a qualified investigator or designee to explain the study to the prospective participant, answer questions, and assess whether they genuinely understand before signing. No AI tool currently performs that function. The signed form documents a human interaction; it is not a replacement for one.

AI tools also do not eliminate the need for IRB review. Every ICF, however it was drafted, must go through institutional and sponsor review before use. Draft-generation tools reduce the time to a review-ready document; they do not bypass the review or transfer regulatory responsibility.

Limitations and Oversight Requirements

Sponsors considering AI tools for ICF development should ensure that any generated content is reviewed by a qualified regulatory affairs or medical writing professional before IRB submission. As of this writing, the FDA has not issued specific guidance on the use of AI in consent form drafting, which means standard document quality and accuracy expectations apply. An AI-generated form containing a substantive error about study risks or procedures is no less problematic from a regulatory standpoint than one containing an error introduced by a human writer.

How Kitsa Fits Into This Problem

Drafting an ICF that accurately reflects a study's procedures, risks, and regulatory requirements involves reading and synthesizing the full protocol, matching required elements against applicable regulations, and producing language accessible to the intended participant population. KScribe, Kitsa's AI-native regulatory document generation engine, is built to support exactly that workflow: generating clinical documents, including ICFs and related regulatory files, from source study data in a way that maintains cross-document consistency and reduces the manual burden on medical writers and regulatory teams. For organizations managing multi-site trials where version control and amendment-driven re-consent create significant operational overhead, a document infrastructure that keeps ICF content aligned with the current protocol is a practical advantage.

Key Takeaways

Frequently Asked Questions

References

You Might Also Like